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1. Summary 
The current challenge in pulmonary drug delivery is to overcome and to control drug 
clearance from the lung. Here, the interaction with the mucociliary lung clearance 
plays a key role for any drug formulation technology. By today many open questions 
on mucociliary clearance (MC) have to be answered but suffer from limited 
experimental options. Considering these facts, the central part of this work was to 
develop a new in vitro test model to investigate the complex mechanism of MC more 
detailed. In a next step the new model was employed to study the influence of 
different factors on mucociliary particle clearance. From the overall results it can be 
concluded that: 
 
 A new embryonic chicken trachea-based in vitro model to study MC was 
successfully developed and characterized. 
 
 The model exhibits a stability and sensitivity for environmental as well as 
chemical influences reflecting the in vivo situation. 
 
 Size and ζ-potential (ZP) seem to be minor critical factors for mucociliary 
particle clearance, which could be shown for different polymeric particles 
covering a broad size and ZP range. 
 
 The chemical surface structure of nanoparticles was found to be a most 
relevant factor for MC, offering promising possibilities to achieve faster or 
slower particle transport. 
 
In summary, this model may help to clarify open questions on lung clearance, strongly 
limiting the benefit of pulmonary drug delivery, and to realize the ‘3R’ concept in 
animal testing: Reduce, Refine, and Replace. 
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2. Zusammenfassung 
Die kontrollierte Arzneistoffelimination aus der Lunge stellt für die Inhalative 
Therapie eine große Herausforderung dar. Von zentraler Bedeutung, doch bis heute 
mit vielen offenen Fragen verbunden, ist hierbei die mukoziliäre Clearance (MC).  
Ziel dieser Arbeit war daher die Entwicklung eines neuen in vitro Modells für die 
gezielte Untersuchung mukoziliärer Transportprozesse sowie die anschließende 
Testung verschiedener Einflussfaktoren auf die MC von Partikeln. Aufgrund der 
Ergebnisse dieser Arbeit können folgende Schlüsse gezogen werden: 
 
 Ein auf embryonaler Hühnertrachea basierendes in vitro Testsystem zur 
Untersuchung der MC wurde erfolgreich entwickelt und charakterisiert. 
 
 Das Modell weist gegenüber äußeren Einflüssen und Arzneistoffen eine mit 
der in vivo Situation vergleichbare Stabilität sowie Sensitivität auf. 
 
 Partikelgröße sowie ζ-Potenzial scheinen für die MC von untergeordneter 
Bedeutung zu sein, was für verschiedene Polymerpartikel unterschiedlicher 
Ladung und Größe gezeigt werden konnte. 
 
 Die chemische Struktur und Oberflächenbeschaffenheit nanoskaliger Partikel 
scheint ein wichtiger Parameter für die MC zu sein und stellt damit einen 
Erfolg versprechenden Ansatz für die kontrollierte Arzneistoffelimination aus 
der Lunge dar. 
 
Zusammenfassend besteht mit diesem neuen in vitro Modell künftig die Option, 
mukoziliäre Transportprozesse unter Beachtung des 3R-Konzepts für Tierexperimente 
(Reduce, Refine, and Replace) gezielt zu untersuchen und aufzuklären. 
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3. General Introduction 
 
 
 
 
 
 
Parts of this chapter will be published in: 
 
Henning A., Hein S., Schneider M., Bur M., Lehr C.-M. (2009): Aerosol Delivery: 
Inhaling Medicines. In: Handbook of Experimental Pharmacology: Novel Drug 
Delivery Approaches; Eds. Hofmann F., Schaefer-Korting M.S., Springer, New York, 
USA. 
 
 
 6
                                                                                                         General Introduction 
3.1. Inhalation in History 
Already several thousand years ago mankind has been employing the respiratory route 
for drug delivery purposes. Ancient Egyptian physicians used the energy of hot stones 
to evaporate alkaloids from plants in order to make their patients inhale the active 
substances (Sanders, 2007). Indian as well as Native American shamans knew about 
the anti-asthmatic effects of Datura stramonium when leaves were smoked in a pipe 
or simply burned within a small room (Dessanges, 2001). Moreover, the smoking of 
opium, containing highly analgesic alkaloids from Papaver somniferum, has a long 
tradition in Chinese culture, although the medical aspect was not of primary relevance 
in this case. Hence, it is not surprising that in the course of time inhalation technology 
as well as the general knowledge of therapeutic inhalation continuously developed, 
and by today still is. In order to make inhalation more effective, the simple smoking 
pipes from the beginning were soon replaced by more ingenious inhalation 
instruments (Figure 1). 
 
 
 
 
 
 
 
 
Figure 1: Historical Inhalation Devices 
Left image: Smoking pipe found at Lake Valencia, in Venezuela. This pipe dates from about 
800 BC to 1200 AD. Cave drawings from this period and region also depict pipes being 
smoked. Right image: The ‘Pneumostat’ was a very early compressor nebulizer manufactured 
by Weil in Frankfurt in the early 1930’s. The ‘Pneumostat’ was used to deliver doses of 
Bronchovydrin (papaverin and eumydrine). By courtesy of Mark Sanders. 
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It was already in 1654 when the first illustration of an inhaler was depicted in 
Christopher Bennet’s Theatri Tabidorum (Bennet, 1654). However, the term “inhaler” 
was introduced in 1778 by John Mudge, an English physician giving advice to treat 
cough via inhalation of opium vapor (Mudge, 1778). Accompanied by the continuous 
technical optimization, the improved understanding of pulmonary drug delivery 
principles also mediated a more defined and accurate vocabulary in this field. 
According to Aiache, it were R. Whitlaw and E. Gray Patterson who defined the word 
“aerosol” in 1932, based on “aer” (air) and “sol” (solution) (Aiache, 1990). Hitherto, 
the terms “mist”, “micromist”, “fog”, and “fume” were used in an imprecise and often 
even confusing manner. This is astonishing from a current view of things, as a defined 
vocabulary is one of the fundamental requirements in every field of today’s science. 
 
The driving force to improve medical inhalation, especially in the 19th century, was 
the treatment of Consumption or pulmonary phthisis, whereas today the focus is given 
more in the treatment of asthma, COPD (Chronic obstructive pulmonary disease), and 
cystic fibrosis (CF) therapy. Till today this development results in a continuously 
increasing number of approved inhalation products as well as new therapeutic 
approaches, such as vaccination via the pulmonary route (Bivas-Benita et al., 2005; 
Lu and Hickey, 2007) and highly specific lung lobe targeting (Selting et al., 2008). 
 
With regard to the current status, several respiratory diseases can be adequately 
treated by inhalation therapy (Groneberg et al., 2003). For many asthma and COPD 
patients, drug inhalation is even suitable to serve as the only form of therapeutic 
intervention. This in fact offers an important advantage regarding the patient’s 
compliance and overall benefit from the therapy. Though, depending on the actual 
status and general severity of the disease, drug inhalation is needed once or several 
times per day. It is of particular importance to note that the correct drug application, 
here inhalation maneuver, results in a superior therapeutic effect and consequently a 
lower application rate (Booker, 2005; Serra-Batlles et al., 2002; Welch et al., 2004). 
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Due to this fact every patient receiving inhalative medication should be thoroughly 
trained in order to optimize drug deposition within the respiratory tract. However, in 
most cases it is rather the suboptimal inhalation technique than other factors, e.g. the 
lungs efficient clearance mechanisms, significantly limiting the success of the 
therapeutic regimen. 
 
3.2. Lung Structure and Resulting Opportunities 
Against the background of a continuously growing medical interest in pulmonary drug 
delivery, the gentle reader may already have scrutinized the scientific and economic 
reasons for this development. First and foremost it is the extremely thin (0.1 -0.5 µm) 
air-blood barrier (Figure 2) and the huge surface area of the lung (~140m2) which 
predominantly contribute to the lungs unique and promising barrier properties for 
pharmaceutical drug delivery. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The Air-Blood Barrier 
The TEM image (cross section) shows the epithelium (ep), the endothelium (en), the basal 
membrane (bm), and erythrocytes (ery) within an alveolar capillary. By courtesy of Peter 
Gehr, Institute of Anatomy, University of Bern, Bern, Switzerland. 
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Considering overall morphology of the lung, the organ consists of at least two 
dissimilar zones: the centrally located conducting airways, and the peripherally 
located respiratory zone. More precisely, the trachea, the main bronchi, and the 
conducting bronchioles account for the conducting airways, whereas the respiratory 
bronchioles, alveolar ducts, and the alveoli account for the lung’s respiratory zone 
(Figure 3). Based on the tree-like branching pattern, the lung’s structure is commonly 
subdivided into particular airway generations, starting with the trachea as 
generation 0, and ending with the alveoli as generation 23 (Albertine et al., 2000). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic Lung Structure 
Left: Human airway structure exhibits symmetric branching from the trachea to the alveolar 
region. Right: In the upper airways a columnar epithelium mainly consisting of ciliated cells 
and goblet cells is found, whereas in the alveolar region a flat and monolayer epithelium is 
formed by alveolar type-I and type-II cells. 
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As might be already assumed from the terminology, the conducting airways’ function 
is mainly limited to air bulk flow during the active in- and exhaling process, whereas 
the essential and to the lungs designated gas-exchange function is exclusively realized 
within the respiratory zone. With regard to the lung epithelium, significant changes 
are present comparing the columnar, ciliated epithelium of the upper airways and the 
monolayer, non-ciliated epithelium of the alveolar region (Forbes, 2002; Forbes and 
Ehrhardt, 2005). 
This unique morphological situation, namely the thin and huge alveolar surface, 
provides promising advantages for pulmonary drug delivery, moreover offering the 
chance to overcome the ‘old problems’ of classical administration routes, e.g. the first-
pass effect and poor bioavailability after oral drug application. Besides these 
morphological aspects of the lung and aiming for a successful delivery concept, 
therapeutic aerosols must be generated and inhaled considering the principals of 
aerosol formation and deposition as is elucidated in the following section. 
 
3.3. Aerosol Deposition within the Lung 
Inside the respiratory system inhaled material deposits in different lung regions 
mainly depending on the aerodynamic particle diameter and the overall inhalation 
maneuver. Discrimination between the deposition sites is realized due to three 
different principal mechanisms: Brownian motion, sedimentation and impaction 
(Heyder, 1981). For particles smaller than 1 μm, Brownian motion will be the decisive 
mechanism for deposition in mainly alveolar regions of the lung. Particles sized  
1–5 μm are suitable to enter and sediment within the tracheo-bronchial region, 
whereas particles larger than 5 μm will mainly be deposited in the oro-pharyngal 
airways due to impaction (Heyder et al., 1986; Oberdörster et al., 2005). 
Interestingly, ultrafine particles of 0.005–0.2 µm are efficiently deposited in the deep 
lungs, whereas most of the particles sized 0.2–1.0 µm are exhaled again (Dolovich et 
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al., 2000; Heyder and Svartengren, 2002). A graphical impression of these important 
aerosol principles and the resulting particle deposition pattern is given in Figure 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Regional Deposition of Particles within the Lung 
Depending on particle size and the overall inhalation maneuver, the particles deposit within 
different regions of the lung. Although ultrafine particles of 0.005 – 0.2 µm are efficiently 
deposited in the deep lungs, this size range is currently not exploited for therapeutic aerosols. 
By courtesy of the Danish EPA (Report No. 12352008). 
 
However, due to a lack of appropriate formulation technologies that can generate 
ultrafine drug particles (0.005–0.2 µm), and along with intrinsic limitations on the 
drug dose these particles can deliver within a reasonable aerosol volume or time of 
inhalation, this size range is not used for aerosol medicines at the moment. 
It is obvious that incorrect pulmonary application inevitably results in a significantly 
reduced therapeutic drug effect. Nonetheless, most inhaled drugs are intended to reach 
the alveolar region, since the very thin epithelium (0.1–0.5 µm) and the huge alveolar 
surface (~140m2) offer superior conditions for drug absorption. Overall the alveolar 
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surface accounts for more than 95% percent of the lungs total surface (Weibel, 1979). 
In this context, a defined and controlled inhalation maneuver is of utmost importance 
for regional targeting and normally intended alveolar deposition of the drug. The 
inspiratory flow rate and total volume act as decisive parameters for regional particle 
deposition (Bennett et al., 1999; Brand et al., 2000; Brown and Bennett, 2004).  
High flow rates (1000 ml/s) are correlated to an increased fraction of particles 
deposited within the central airways, whereas at slow flow rates (200 ml/s) the chance 
for alveolar deposition is increased (Scheuch et al., 2007). Accordingly, a major 
paradigm in aerosol drug delivery may be defined as “slow and steady wins the race” 
(Dhand, 2005). 
So far the efficacy of many commercially available inhalation products still suffers 
from a big fraction of drug deposited in the airways (Hochrainer et al., 2005; Pitcairn 
et al., 2005). It is important to note that several more efficient technologies are 
available and hopefully will improve future inhalation therapy (Scheuch and Fischer, 
2008; Scheuch and Siekmeier, 2007). However, the augmented use of such raising 
technologies is limited by the economic hurdles most new and cost intensive concepts 
are facing. In summary and with regard to pulmonary drug delivery devices, the work 
from the device or engineering side is mainly done, passing now the ball to the 
‘scientific team’ to clarify what happens after the controlled deposition of the drug. 
 
3.4. Lung Clearance Mechanisms 
3.4.1. Airway Clearance 
In parallel to the dissimilar morphological structure, there are also distinctive 
differences between clearance mechanism in the airways and the alveolar region. 
Deposition in the conducting airways normally occurs with particles or pathogens 
adhering to the sticky mucus layer lining the airway surface. Mucosal barriers in 
general can be found at various sites of the human body, lining the gastro intestinal 
 13
                                                                                                         General Introduction 
tract, intranasal epithelium, airways and more. In all cases the mucosal barrier serves 
as a shelter intended to protect the human body from exogenous influences such as 
bacteria, viruses or fungal spores. These pathogens normally interact with the viscous 
mucus layer, hence are immobilized and will be eliminated by clearance mechanisms 
present at the specific body sight. 
Airway mucus is a viscous gel composed of highly glycosylated mucus proteins also 
called mucins (Desseyn et al., 2000; Thornton et al., 2008). After entrapment by the 
mucus layer, particles and pathogens are subsequently cleared from the deposition site 
as the mucus continuously moves proximally towards the upper end of the tracheal 
tube (Figure 5). Unidirectional mucus transport is realized due to energy transfer from 
beating cilia to the upper mucus layer. Airway cilia (~200 cilia per cell) are hair like 
cell appendages (5-7 µm) beating in a metachronal coordinated wave pattern, thereby 
transferring kinetic energy to the upper mucus layer during the forward stroke (Sleigh 
et al., 1988). Finally, entrapped material and mucus are swallowed and undergo 
further biochemical processing in the gastrointestinal tract. 
 
 
 
 
 
 
 
 
 
 
Figure 5: Mucociliary Clearance Scheme 
After the particle deposited on the sticky airway mucus, both the mucus layer and the 
entrapped particle are cleared towards the upper end of the trachea. Continuous transport of 
the mucus layer is based on the metachronal beating of cilia. 
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In view of the average tracheal clearance velocity, as determined by noninvasive 
radiological techniques in healthy non-smokers, mucociliary clearance varied between 
4.0 and 6.0 mm/min (Hofmann and Asgharian, 2003). Based on these results, the 
International Commission on Radiological Protection (ICRP) and the National 
Council on Radiological Protection (NCRP) adopted an average tracheal clearance 
velocity of 5.5 mm/min (ICRP, 1994; NCRP, 1997). 
 
3.4.2. Alveolar Clearance 
Drugs and particles that have been successfully deposited in the alveolar region will 
not be cleared by mucociliary clearance, since no ciliated cells are present in the deep 
lung. Here, alveolar macrophages (Figure 6) are the main important mechanism to 
defeat inhaled pathogens, particles and more (Moeller et al., 2005; Sibille and 
Reynolds, 1990). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Top view of alveolar epithelium (SEM) 
In the alveolar region, pathogens and inorganic particles are normally eliminated by alveolar 
macrophages, patrolling on the alveolar surface (see bottom left). By Courtesy of the 
Lawrence Berkeley National Laboratory. 
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Adult macrophages, derived from monocytes within the bone marrow, migrate 
towards the alveoli and patrol on the alveolar surface. With regard to the rate of 
particle elimination Geiser et al. were able to show that ultrafine TiO2 particles, 
deposited in the lung of rats, are phagocytosed by the alveolar macrophages within 
hours (Geiser et al., 2005). Subsequently, alveolar macrophages either undergo 
mucociliary clearance upon ascending to the airways or actively migrate into the 
alveolar lymphatics for further involvement into immunomodulatory processes. 
 
Comparing mucociliary airway clearance and alveolar clearance, the latter is unlikely 
to act as the limiting factor in inhalation therapy for several reasons: 
 
 Many marketed products still suffer from poor drug delivery to the deep lung, 
consequently the active agent is mainly deposited in the airways. 
 
 The alveolar surface accounts for about 95% of the lungs total surface, thus 
alveolar clearance, even if alveolar and airway clearance mechanisms would 
be comparable in efficiency, is unlikely to be as effective as mucociliary 
airway clearance. 
 
 Considering the prevailing morphology in the airways versus the alveolar 
region, any drug or particle must overcome the thick and highly viscous 
airway mucus barrier, whereas the thin alveolar surface is designed for 
absorptive processes per se. 
 
Consequently, mucociliary clearance (MC) essentially limits the benefit of many 
inhalation therapies: after initial inhalation and deposition, drug particles are 
rapidly cleared (4-6 mm/min!) and thus removed from the intended target site. 
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3.4.3. Mucociliary Clearance – State of the Art 
 
Several in vivo as well as in vitro approaches have been realized in order to determine 
and investigate mucociliary transport rates (MTR) of drugs/particles in humans and 
animals. Due to anatomical as well as experimental reasons, direct in vivo 
measurements are complicated and presently available only for the human trachea 
(Foster et al., 1982; Leikauf et al., 1981; Mussatto et al., 1988; Toomes et al., 1981; 
Yeates et al., 1982). 
The use of different experimental in vivo techniques produced a wide variability in the 
measured human MTR values, ranging from 3.6 to 21.5 mm/min. Reported tracheal 
MTR in rats and other animal species also display a wide range of values, presumably 
resulting from different experimental techniques as well (Hofmann and Asgharian, 
2003). Hence, placing emphasis on the ethical aspects of such experiments, one might 
be in doubt about the scientific value of these results. 
In order to overcome this unfavourable situation for in vivo studies, Rubin et al. 
developed the in vitro ‘frog palate model’ to investigate mucociliary clearance more 
detailed (Rubin et al., 1990). Leopard frogs (Rana pipiens) or bullfrogs (Rana 
catesbiana) are prepared by double pithing, i.e. bending the head forward and 
inserting a needle into the brain and the spinal cord. Subsequently, the jaw is 
disarticulated and the palate removed by cutting through from the junction of the 
posterior pharynx and oesophagus out to the skin of the back. The excised frog palate 
is focused under a dissecting microscope fitted with a micrometer scale, and the 
movement of mucus or entrapped particles is timed. At first instance, this model 
seemed to be a good approach to assess in vitro mucociliary clearance. Unfortunately, 
it turned out later that mucus transport on the frog palate was strongly influenced by 
season and other undetermined factors (Rubin et al., 1992). Besides this amphibian 
based concept, other researchers employed bovine or horse trachea explants to 
investigate in vitro mucociliary clearance (Gerber et al., 1997; Wills et al., 1995). 
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Though, both in vitro models require active treatment of the mucus which is likely to 
alter the native mucus properties and mucociliary transport rates in consequence. 
 
Overall, in vivo studies on mucociliary clearance face many regulatory, ethical, and 
experimental problems; not least since it was shown that anaesthesia, which hardly 
can be avoided in these experiments, significantly influence mucociliary clearance 
rates (Ledowski et al., 2008; Ledowski et al., 2006). On the other hand, yet existing  
in vitro models often suffer from limited resources, time-consuming preparation, and 
critical preparation steps, such as chemical mucus depletion. 
                                                                                                              Aim of this Work 
 
4. Aim of this Work 
It is the extremely thin air-blood barrier (0.1 - 0.5 µm) and the huge surface area of the 
respiratory tract (~140m2) which predominantly contribute to the lungs unique and 
promising barrier properties for pharmaceutical drug delivery. Nevertheless, 
mucociliary clearance still is a critical factor in pulmonary drug delivery, significantly 
limiting the therapeutic benefit of many inhalation therapies. Although the basic 
principles of mucociliary transport seem to be understood, there are many open 
questions on e.g. mucus-particle interaction and particle transport rates; not at least 
since the actual possibilities to investigate mucociliary clearance are rather limited and 
suboptimal. To overcome mucociliary clearance, a more detailed understanding of this 
clearance mechanism seems to be crucial and inevitable. In a next step, systematic 
studies utilizing different drug delivery approaches will be needed to identify most 
promising strategies. Consequently, the scientific demand for a new and more feasible 
in vitro method was obvious and the driving force behind the work presented here. 
 
The major aims of this thesis were: 
 
1) To develop a new and feasible in vitro method, avoiding ethical as well as 
regulatory hurdles, to investigate mucociliary particle clearance.  
 
2) To test the influence of critical parameters, such as temperature, 
humidity, and ciliotoxic drugs on mucociliary particle clearance. 
 
3) To investigate clearance rates of different nanocarriers in order to 
identify parameters and promising strategies to overcome mucociliary 
drug/particle clearance. 
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5. Development of the Embryonic Chicken Trachea (ECT) 
Based In Vitro Clearance Model 
 
 
 
 
 
 
Parts of this chapter have previously been published in: 
 
Henning A., Schneider M., Bur M., Blank F., Gehr P., Lehr C.-M. (2008): Embryonic 
chicken trachea as a new in vitro model for the investigation of mucociliary particle 
clearance in the airways. AAPS PharmSciTech, 9(2):521-527. 
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5.1. Abstract 
Mucociliary clearance (MC) is an important defense mechanism of the respiratory 
system to eliminate inhaled and possibly noxious particles from the lung. Although 
the principal mechanism of MC seem to be relatively clear there are still open 
questions regarding mucociliary clearance of particles. Therefore, we have developed 
a new set-up based on embryonic chicken trachea (ECT) to investigate mucociliary 
particle clearance and related topics in more detail. ECT was placed in an incubation 
chamber after carbon particles were applied and tracked using optical microscopy. 
The aim of the study was to validate this new model by investigating the impact of 
temperature, humidity and drugs on mucociliary particle transport rates. 
Particles were transported reproducibly along the trachea and clearance velocity  
(2.39 ± 0.25) mm/min was found to be in accordance to data reported in literature. 
Variation in temperature resulted in significantly reduced MC: (0.40 ± 0.12) mm/min 
(20°C); (0.42 ± 0.10) mm/min (45°C). Decreasing humidity (99% - 60%) had no 
significant effect on MC, whereas reduction to 20% humidity showed a significant 
influence on particle clearance. The use of different cilio- and mucoactive drugs, i.e. 
Propranolol, Terbutalin, and N-Acetylcysteine, resulted in altered MC according to 
the pharmacological effect of the substances: a concentration dependent decrease of 
MC was found for Propranolol. 
 
From our results it is concluded that this new in vitro model can be employed to 
investigate mucociliary particle clearance in more detail. Hence, the model may 
help to understand and identify decisive physico-chemical parameters for MC 
and to answer open questions regarding the long-term clearance phenomenon, 
mucus-particle interactions, and more. 
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5.2. Introduction 
The human lung as application site for active substances is of increasing importance 
for local (e.g. asthma, COPD) as well as systemic (e.g. Diabetes mellitus) therapy. 
The attractiveness of pulmonary drug delivery is attributed to the good absorption due 
to a huge alveolar surface area (70-140m²), unique barrier properties and avoidance of 
the first-pass effect (Corkery, 2000). Beside these therapeutic aspects there is a 
constant input of exogenous material into the lung triggered by breathing. Here, 
mucociliary clearance (MC) is a most important mechanism to eliminate inhaled and 
possibly noxious particles, bacteria and toxins from the central airways. 
In the field of inhalation toxicology the aerodynamic diameter is termed to be a main 
decisive parameter. Particle classification is based upon a precise nomenclature which 
is inevitable for avoiding misunderstanding and confusion. Thus, ultrafine particles 
(UFP) are defined to be smaller than 100 nm in diameter, whereas particulate matter 
(PM) can be divided into inhalable PM10 (d < 25 µm) and respirable PM2.5  
(d < 3.5 µm). Depending on the aerodynamic diameter and the inhalation maneuver, 
particles will deposit in different regions within the respiratory system (Scheuch et al., 
2007). Discrimination between deposition site of the particles is realized due to three 
different principal mechanisms: impaction, sedimentation and Brownian motion 
(Heyder, 1981). Particles sized > 5 µm will mainly be deposited in the oro-pharyngal 
region due to impaction, whereas particles sized 1-5 µm are suitable to enter the 
tracheo-bronchial region. When particle size is reduced to ≤ 1 µm, Brownian motion 
will be the decisive mechanism for deposition in mainly peripheral regions of the lung 
(Oberdörster et al., 2005). 
To date exclusive deposition in either the bronchial or the alveolar region is not 
feasible and only can be optimized using special inhalation techniques, e.g. the 
shallow bolus technique for targeting the airways (Brand et al., 1995; Scheuch et al., 
1989). Depending on the site of particle deposition, clearance is realized by different 
mechanisms: a) Mucociliary clearance (MC): the airways are covered by a mucus 
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layer that is transported by ciliary beating resulting in a fast removal of deposited 
particles. b) Alveolar macrophages: in the lung periphery no ciliated cells are present 
and alveolar macrophages are the defense mechanism in this region (Möller et al., 
2004). As the present work describes the set-up of an in vitro test system to investigate 
mucociliary clearance, a closer look at the detailed morphological architecture, 
conditions and prerequisites in this area is appreciated. 
 
In healthy individuals the mucus layer consists of the upper gel layer and the lower 
periciliary layer. The periciliary layer is a low viscosity fluid with a thickness of  
5-7 µm which is slightly less than an extended cilium (Marttin et al., 1998). The 
mucus layer on top is a gel composed of a 3-dimensional polymer network of mucus 
glycoproteins or mucins. These mucin macromolecules are 70-80% carbohydrate, 
20% protein and 1-2% sulphate bound to oligosaccharide side chains (Fuloria and 
Rubin, 2000; Matsui et al., 1998). About 3% of the mucus layer consist of mucins, 
while 90-95% consist of water, with electrolytes, serum proteins, immunoglobulins 
and lipids (Lethem, 1993; Verdugo, 1990). 
Although optimum concentration for all components seems likely to exist, MUC5-AC 
and MUC5-B have been identified to be predominantly responsible for gel-forming 
and adhesive properties of airway mucus (Gray et al., 2001; Lillehoj and Kim, 2002). 
Alterations in secretion rate and MUC5-AC to MUC5-B ratio correlated with 
impaired mucociliary clearance can be found in several pathophysiological conditions 
of the respiratory system e.g. asthma, cystic fibrosis and COPD (Groneberg et al., 
2002a; Groneberg et al., 2002b; Kirkham et al., 2002). 
With regard to the human airway epithelium, 30-65% of the total airway epithelium 
are covered with ciliated cells, whereat each cell houses about 200 cilia (Blake and 
Sleigh, 1974). Cilia are motile hair-like appendages extending 5-7 µm from the 
surface of epithelial cells. They contain a central axoneme i.e. a bundle of 
microtubules arranged as nine outer doublets and one central pair (9*2+2 
arrangement) (Satir and Christensen, 2007). Movement of the cilium is generated by 
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sliding movements of the microtubules under ATP depletion (Afzelius, 2000). Cilia 
beat in close coordination and adjust their frequency and phase of beating in response 
to neighboring cilia (Sleigh et al., 1988). Throughout the ciliary beat cycle, consisting 
of forward and backward stroke, cilia transfer kinetic energy to the on top located 
mucus layer predominantly during the forward stroke. Metachronal coordination and 
beat mechanics result in transport of the mucus layer towards the oesopharyngal 
region, where finally the mucus and entrapped material is swallowed. 
Former studies could show that mucociliary clearance removes all particles larger than  
6 µm in diameter within 24 hours from the human airways in vivo. For particles 
smaller than 6 µm a certain fraction was retained for more than 24 hours. Further 
reduction in particle size correlated with an increasing fraction of long-term cleared 
particles (Scheuch and Stahlhofen, 1987; Stahlhofen et al., 1986; Stahlhofen et al., 
1990). Despite the phenomenon of long-term cleared particles, the effects of inhaled 
ultrafine particles and particulate matter on human health have been for years and still 
are under debate (Kreyling et al., 2006). However, the number of epidemiological 
studies indicating a correlation between exposure to particulate matter and adverse 
health effects increases constantly (Annesi-Maesano et al., 2007; Dominici et al., 
2006). 
 
By today the decisive parameters and mechanisms of particle long-term clearance are 
not understood and different hypotheses are under discussion: Depending on particle 
size and physico-chemistry a certain fraction of particles might penetrate into and 
through the mucus layer and thus escape from mucociliary clearance (Gehr et al., 
1993; Gehr et al., 1996; Geiser et al., 2000; Peters et al., 2006; Schurch et al., 1990). 
In case that the mucus layer is not a fully closed blanket covering the surface of all 
airways, particles might penetrate directly into the periciliary layer after deposition 
and thereby undergo fast elimination (Iravani and As van, 1972; Matsui et al., 1998). 
Another reason for delayed clearance is possibly the deposition of a certain particle 
fraction in the peripheral lung although the airways are the primary target. 
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The aim of our study was to set up an in vitro model based on embryonic chicken 
trachea (ECT) to investigate mucociliary particle clearance under more complex 
constraints such as various temperatures, humidities and drugs. Histochemical 
characterization of the model was performed in order to check for functional 
development of ciliated cells, goblet cells, surfactant proteins, and differences 
compared to human tissue morphology. 
 
Overall, this model will allow for exploring mucociliary clearance and mucus-particle 
interactions based on functional interaction of cilia and mucus. It is well suited for this 
approach since former experiments showed that embryonic chicken trachea is a valid 
substitute for human material in studying ciliary beat frequency and ciliary toxicity 
(Boek et al., 1999a, b; Merkus et al., 2001; Van De Donk et al., 1982). 
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5.3. Materials and Methods 
5.3.1. Materials 
Inorganic salts (E. Merck, Darmstadt, Germany); Activated carbon Ph.Eur. (E. Merck, 
Darmstadt, Germany); Fertilized chicken eggs (Lohmann Tierzucht GmbH, 
Cuxhaven, Germany); Octadecyltrichlorosilane (E. Merck, Darmstadt, Germany); 
Propranolol hydrochloride (Sigma-Aldrich Chemie GmbH, Steinheim, Germany); 
Terbutalin hemisulfate (Sigma-Aldrich Chemie GmbH, Steinheim, Germany); N-
Acetylcysteine (Sigma-Aldrich Chemie GmbH, Steinheim, Germany); Uranyl acetate 
(Fluka AG, Zuerich, Switzerland); Lead citrate (Leica AG, Heerbrugg; Switzerland); 
Eppon resin (Fluka AG, Zuerich, Switzerland); Alcian Blue, 8GX standard (Sigma-
Aldrich Chemie GmbH, Steinheim, Germany); Protein marker, SDS-Page standards, 
low range (BioRad, Muenchen, Germany); Anti-Surfactant Protein A, AB3420 
(Millipore, Schwalbach Germany, formerly Chemicon); Goat anti-rabbit IgG, 
Alkaline Phosphatase conjugate, AP132A (Millipore, Schwalbach Germany, formerly 
Chemicon); NBT/BCIP Stock Solution (Roche Diagnostics Corporation, Indianapolis, 
USA). All chemicals used in the experiments were of highest available quality. 
 
5.3.2. Breeding 
Chicken eggs of SPF quality (specific pathogen free) were incubated in a breeding 
chamber (Hemel Breeding Instruments GmbH, Verl, Germany) at 37.8°C and 60% 
relative humidity for 19-20 days. During breeding, eggs were automatically turned 6 
times per day, including a cooling period of 1 hour per day, to supply optimal 
conditions for development of the chicken embryo. Development of the chicken 
embryos was controlled by weighing as well as candling of the eggs (Figure 7A, 7B). 
Egg candling includes placing the egg on a plastic ring and subsequent illumination 
from below, using a regular 60W light bulb as light source. Thereby, a normal or 
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abnormal development status of the chicken embryo was ascertained by visual 
examination. Non-fertile eggs were displaced from the breeding chamber in order to 
minimize the risk of microbiological contamination of other eggs. 
 
A)  
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
Figure 7: Breeding controls 
A) The upper graph shows the results of egg weighing over the course of time. A non-fertile 
egg, indicated by the red arrow, shows an abnormal loss of weight during incubation in the 
breeding chamber. B) The picture series shows candling results at different stages of normal 
chicken embryo development. Normal or abnormal development status of a chicken embryo 
was ascertained by combined visual examination and weighing results. 
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5.3.3. Clearance Experiments 
All clearance experiments were performed using freshly harvested embryo chicken 
trachea (Figure 8). After dissection the trachea was placed on gauze soaked with 
Locke-Ringer solution (LR). LR is an isotonic solution of NaCl 7.72g (132 mmol), 
KCl 0.42g (5.63 mmol), CaCl2 x H2O (0.16g / 1.24 mmol), NaHCO3 (0.15g / 1.79 
mmol) and glucose anhydrous (1.00g / 5.55 mmol) in 1 litre of water. Prior to particle 
deposition the tracheal tube was cut oblong resulting in 2 tracheal half-pipes. Particle 
deposition on the half-pipes was realized utilizing a Dry Powder Insufflator™ Model 
DP-4 (PennCentury Inc., Philadelphia, USA) adopted from instillation experiments 
(Sakagami, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Breeding and Trachea Preparation 
After breeding for 19-20 days (37.8°C; 60% rel. humidity) the embryonic chicken trachea was 
harvested and cut oblong. Subsequently, particles were deposited on the tracheal mucus and 
clearance was timed using appropriate imaging techniques. 
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Following particle deposition the tracheal tissue was transferred to a temperature and 
humidity controlled incubation chamber and subsequently placed under the 
microscope (Figure 9, Annex A.3). 
 
 
Figure 9: Experimental Set-up (see also Annex A.3) 
Left: Incubation chamber placed under the microscope objective. The upper (yellow) part of 
the incubation chamber can easily be removed after turning the magnetic fixation by 45°. 
Right: In order to control the experimental temperature as well as humidity, the microscope 
was fully integrated within the isolation box. 
 
To avoid critical fogging of the incubation chamber, the glass windows were modified 
using surface silanization methodology (Loebau et al., 1996; Metwalli et al., 2006). 
Briefly, the glass substrates were cleaned using a general glass cleaning protocol: 
immersion in NaOH (2.5 M) solution for 24 h, sonication in distilled water for 10 min, 
immersion in HCl (0.1 M) for 15 min, sonication in distilled water for 10 min and 
immersion in methanol for 5 min prior to the silanization step. Silanization of the 
glass substrates were performed by dip coating in 1% aqueous solutions of 
octadecyltrichlorosilane (OTS) for 15 min. Post-treatment steps include shaking in 
methanol for 5 min, rinsing in water for 10 min and finally spin drying (2000 rpm) for 
5 min. The coated slides were baked at 110°C for 15 min and stored in a vacuum 
desiccator prior to use.  
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Carbon particles were applied as model particles to establish the experimental set-up 
due to easy visualization by transmission light microscopy. Particle size was 0.8–
260 µm as determined by static light scattering (MasterSizer-2000, Malvern Inst., 
UK). Particle transport on the trachea was recorded for 10-20 seconds (AxioCam 
HSm, ZEISS, Germany) at various positions on the tracheal half-pipes using a LD 
Plan-Neofluar 10x/0.30 objective (ZEISS, Germany). Particle clearance velocity was 
calculated from 3-8 videos, and 3-6 single particles were calculated per video.  
The effects of three drugs, i.e. Propranolol, Terbutalin and N-Acetylcysteine, already 
known to influence either ciliary beat frequency (CBF) or viscoelastic nature of the 
mucus layer, have been investigated. Tracheal tubes were incubated for 60 seconds in 
LR/drug solution or drug free LR solution (control) prior to particle deposition. A 
significant effect for Propranolol 1% (m/v) on CBF was already reported by Boek 
(Boek et al., 1999a). To investigate the model’s sensitivity for a concentration 
dependent effect on mucociliary particle transport we tested Propranolol at 1% (3.4 
mM), 0.1% (0.34 mM) and 0.01% (3.4 µM). Terbutalin and N-Acetylcysteine were 
both tested at 1% (m/v). 
The influence of temperature (20-45°C) and humidity (20-99%) was investigated to 
test the model’s robustness for various experimental conditions. Temperature and 
humidity in the incubation chamber were actively controlled and monitored online 
using a system provided by LIS (Life Imaging Services, Reinach, Switzerland). 
Results were examined for statistical differences by ANOVA using routine statistical 
software (SigmaStat 3.0). 
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5.3.4. Histochemical Characterization 
 
Histochemical studies were realized in order to check for normal and functional 
development of ciliated cells, goblet cells, surfactant proteins (SP), and potential 
differences compared to human tissue morphology. 
 
SEM/ TEM imaging: 
For SEM imaging tracheal tissue was cut into slices of about 5 mm in width, 
dehydrated in ethanol, critical point dried and sputter-coated with gold. Samples were 
examined using a Philips XL 30-FEG scanning electron microscope (Philips AG, 
Zuerich, Switzerland) operating at 10 kV. For TEM imaging tissue was fixed for 24h 
in 0.03 M potassium phosphate buffer containing 2.5% glutar aldehyde. After fixation 
tissue was embedded in Eppon resin and cut to ultra-thin sections (60-80 nm) as 
described earlier (Gehr et al., 1978). The ultra-thin sections were transferred to 
uncoated 200-mesh copper grids and stained with uranyl acetate and lead citrate 
before examination. 
 
Histology on formalin-fixed lung specimen: 
Alcian blue, a group of polyvalent and basic dyes including copper in their molecule 
structure, was used to stain the tracheal sections. Strongly acidic sulfated or 
carboxylated mucosubstances (glycosaminoglycans) and mucins (glycoproteins) will 
be stained blue, nuclei will be stained pink to red, and cell cytoplasm will be stained 
pale pink. Tracheal tissue was fixed in 10% neutral-buffered formalin and embedded 
in paraffin at 58°C. Sections of 5 µm thickness were cut from the paraffin-embedded 
tissue and mounted on glass slides. Following on incubation in distilled water for 5 
min the sections were transferred and stained with Alcian blue pH 2.5 (1% Alcian 
blue in 3% aq. Acetic acid) for 15 min. After thoroughly rinsing the sections in 
distilled water and counterstaining with neutral red for 1 min, rapid dehydration in 
absolute alcohol was used to fix the copper complex (Prophet et al., 1994). After a 
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final drying step the sections were examined microscopically to check for successful 
staining of the tissue compartments. 
 
5.3.5. Surfactant Protein Analysis 
Due to the relevance of surfactant proteins at the air-liquid interface, and presumably 
at the particle-mucus interface, the embryonic chicken trachea was analyzed for the 
presence of SP-A, the major protein in lung surfactant representing about 5–6% of its 
dry weight (Haagsman and Diemel, 2001). Freshly isolated embryonic chicken 
tracheas were rinsed with distilled water (3 x 5ml) in order to isolate the surfactant 
layer including the surfactant proteins from the inner tracheal surface. As positive 
control, fresh porcine tracheas from the local abattoir were processed in the same 
manner. Protein concentrations in the resulting solutions were determined using the 
BCA-Protein assay (Smith et al., 1985). Protein electrophoresis (15µg) was performed 
by SDS-PAGE (12% gels/ 180 min/ 80V) according to the method described by 
Laemmli (Laemmli, 1970). Western blotting (90 min/ 300mA) and subsequent 
immunostaining (Anti-SP-A: 1:5000) was employed for specific detection of SP-A in 
the embryonic chicken as well as porcine trachea lavage (Amin et al., 2001).  
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5.4. Results 
5.4.1. Proof of Principle 
Mucus and particles were clearly and reproducibly transported along the tracheal 
tissue. An exemplary video sequence on mucociliary particle transport is shown in 
the Annex (A.1). Clearance due to mucociliary interaction was successfully 
demonstrated by turning one of two tracheal half-pipes by 180°: particles were 
transported into different directions but always to the proximal end of the trachea 
(Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Proof of Principle 
The picture shows the cleared inner half-pipes and the resulting accumulation of carbon 
particles at the proximal end of the trachea. In the clearance experiment (top view), carbon 
particles were transported into different but uniquely proximal direction after turning one of 
the tracheal half-pipes by 180°.  
 
Furthermore, the tracheal mucus exhibited characteristic appearance, i.e. mucus 
streams and mucus flakes. Mucus transparency was according to the mucus grades 
(MG) classified by Gerber et al. (Gerber et al., 1997). Completely transparent mucus 
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(MG-1), transparent but slightly opaque mucus (MG-2), opaque mucus with slight 
surface relief (MG-3), and non-transparent, completely opaque mucus with marked 
surface relief (MG-4) were present on the tracheal epithelium. 
 
5.4.2. Validation of the Experimental Set-up 
As it was our intention to study the influence of temperature and humidity on 
mucociliary particle clearance, the overall experimental set-up was characterized with 
regard to its insulating properties. Temperature and relative humidity were measured 
in both the inlet and the outlet airflow of the incubation chamber (A.3B, page 76) and 
revealed no significant differences. After all instruments were switched on (t0) the 
progression of temperature and humidification within the incubation chamber was 
determined (N = 3) after different predetermined time intervals (Figure 11, 12). 
 
 
 
 
 
 
 
 
 
Figure 11: Experimental Set-up: Course of Temperature 
From the graph it is obvious that equilibration time to ensure temperature stability must be 
adapted to the aimed and particular experimental temperature. 
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Comparing the course of humidity and temperature, the latter seems to be a more 
critical factor within our experimental set-up. A temperature of 20°C, 33°C, and 45°C 
was assured after 60 min, 90 min, and 210 min, respectively (Figure 11). In contrast, a 
relatively short equilibration time of about 60 min was suitable to provide 99% 
relative humidity for all different levels of temperature (Figure 12).  
 
 
 
 
 
 
 
Figure 12: Experimental Set-up: Course of Humidity 
Within the incubation chamber a relative humidity of 99% could be ensured after less than 
60 min for all tested levels of temperature. 
 
From the results of these validation experiments it is obvious that lead times to assure 
temperature and humidity equilibrium within the set-up must be adapted to the 
intended and aimed experimental temperature. Therefore, an equilibration period of 
180 min was realized in all our experiments at 20°C and 33°C, and 210 min lead time 
for the studies at 45°C.  
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5.4.3. Temperature and Humidity 
Decrease (20°C) as well as increase (45°C) in temperature resulted in significant 
reduction (P ≤ 0.001) of mucociliary particle transport rates (MTR). MTR determined 
for 20°C, 33°C and 45°C was (0.40 ± 0.12) mm/min, (2.39 ± 0.25) mm/min and 
(0.42 ± 0.10) mm/min, respectively (Figure 13). 
Variation of relative humidity between 60% and 99% had a non significant effect  
(P ≤ 0.001) on particle transport. MTR was (2.29 ± 0.96) mm/min, (2.32 ± 0.70) 
mm/min and (2.39 ± 0.25) mm/min for 60%, 75%, and 99% relative humidity 
experiments, respectively. Further reduction to 20% relative humidity resulted in 
significantly decreased clearance rates (0.54 ± 0.37) mm/min (P ≤ 0.001). 
 
Figure 13: Influence of Temperature on MTR 
Decreased (20°C) as well as increased (45°C) temperature resulted in significant reduction of 
particle transport rates (* P ≤ 0.001). Numbers beside the bars e.g. “100/6” represent a total of 
100 particles tracked on 6 tracheas. 
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5.4.4. Influence of Drugs 
Particle clearance under influence of 3 drugs known to affect mucociliary clearance, 
namely Propranolol, Terbutalin, and N-Acetylcysteine was investigated (Figure 14). 
Propranolol (Pp) was capable of reducing or fully eliminating particle transport in a 
concentration dependent manner. No transport of particles could be observed after 
incubation in Pp-1% (3.4 mM) and Pp-0.1% (0.34 mM) LR/drug solution. Incubation 
in Pp-0.01% (0.034 mM) LR/drug solution resulted in significantly (P ≤ 0.001) 
reduced transport (0.44 ± 0.21) mm/min compared to control experiments (C) (3.14 ± 
0.41) mm/min, using only LR solution. Particle clearance under influence of 
Terbutalin (T) was significantly increased (P ≤ 0.001) to (4.90 ± 0.62) mm/min, 
whereas N-Acetylcysteine (NAC) decreased particle transport significantly 
(P ≤ 0.001) to (0.66± 0.20) mm/min. 
 
Figure  14: Influence of Drugs on MTR 
Clearance velocity under the influence of drugs was significantly changed (* P ≤ 0.001). 
Terbutalin (1%) increased, whereas N-Acetylcysteine (1%) and Propranolol (0.01%) reduced 
mucociliary particle clearance.  
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5.4.5. Histochemical Characterization 
 
To assure presence of the morphological as well as histochemical factors required for 
functional mucociliary clearance, the epithelial topology of the embryonic chicken 
trachea as well as ultrastructure of the cilia was studied using Scanning Electron 
Microscopy (SEM) and Transmission Electron Microscopy (TEM). 
 
TEM / SEM Imaging: 
Cilia were found to be comparable to human respiratory cilia regarding cilia length  
(5-7 µm) and ultrastructure of the microtubules (Figure 15). The typical ‘9*2+2’ 
arrangement of the inner (axoneme) and outer microtubules as well as the radial 
spokes can be clearly seen in the TEM studies. Morphology of the basal bodies, a 
basic parameter for functional and coordinated ciliary beating, exhibited normal 
topology and orientation. Microvilli were present in a characteristic manner at the 
epithelium surface. 
 
 
Figure  15: Cilia Morphology (TEM) 
Left: Cross section of cilia; Outer Microtubules (OMT), Inner Microtubules (IMT), Radial 
Spokes (RS), Plasma Membrane (PM). Right: Cross section of embryonic chicken trachea 
epithelium; Tight Junctions (TJ), Microvilli (MV), Cilia (C). 
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Employing Scanning Electron Microscopy (SEM) to visualize and investigate the 
tracheal surface resulted in a surprising outcome: Interestingly, airway macrophages 
are already present in the embryonic state of the chicken development, as several 
SEM studies revealed airway macrophages adhering to the tracheal surface epithelium 
(Figure 16A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16A: Tracheal Surface (SEM) 
The picture shows an airway macrophage patrolling on the tracheal surface of the embryonic 
chicken trachea. The tracheal epithelium exhibits typical airway morphology consisting of 
ciliated cells and non-ciliated goblet cells. 
 
Furthermore, and in parallel to the previous TEM studies, SEM studies at different 
levels of magnification revealed a normal topology and distribution pattern of cilia, 
ciliated cells, and goblet cells (Figure 16B). The mucus layer, normally located on top 
of the ciliated airway epithelium, is not present in these studies as the trachea was 
several times rinsed with water in order to remove the mucus for imaging purposes. 
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Figure 16B: Tracheal Surface (SEM) 
Cilia on ciliated cells and non-ciliated, mucus producing goblet cells exhibit a characteristic 
topology and distribution pattern.  
 
Paraffin sections: 
Cross sections of the tracheal tissue showed normal morphology regarding cilia length 
and cilia density. Presence of goblet cells and of the airway mucus layer was 
successfully determined via characteristic Alcian blue staining (Figure 17, next page). 
Acidic mucins and mucosubstances present in the mucus layer, goblet cells, and 
hyaline cartilage are stained in deep blue. Cell cytoplasm and nuclei are typically 
stained in reddish and pink.  
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Figure 17: Alcian Blue Staining of Paraffin Embedded Tracheal Tissue. 
The mucus layer (M), goblet cells (GC), and hyaline cartilage (HC) are present and exhibit 
characteristic staining. Cilia (C) on ciliated cells (CC). x100 cross section 
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5.4.6. Surfactant Protein Analysis 
Lung surfactant is a complex mixture of lipids and proteins lining the inner surface of 
respiratory tract (Wright, 2004). Surfactant has two distinct functions. First, it reduces 
surface tension at the air-liquid interface of the lung - this function requires an 
appropriate mix of surfactant proteins and lipids. Second, surfactant also plays an 
important role in host defense against infection and inflammation. Due to the 
relevance of surfactant proteins at the air-liquid interface, the embryonic chicken 
trachea was analyzed for the presence of SP-A, the major protein in lung surfactant 
representing about 50% of the total surfactant protein mass (Hawgood, 1997). As can 
be seen from the experimental result, detection of SP-A in both embryonic chicken 
and porcine trachea lavage was positive (Figure 18).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: SP-A Immunoblot of Embryonic Chicken and Porcine Trachea Lavage. 
For both the embryonic chicken (ECT) and the porcine (Porc.) trachea lavage a positive and 
characteristic immunoblot for SP-A could be observed.  
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Multiple bands in the range between 26-38 kDa and 50-70 kDa exhibit a characteristic 
distribution pattern and result from the multimeric SP-A structures and the multitude 
of post-translational SP-A modifications (Hermans and Bernard, 1999). A weaker 
signal for ECT in comparison to the porcine signal presumably results from a lower 
relative SP-A concentration in the ECT lavage, or a generally reduced antibody 
affinity for chicken SP-A multimers.  
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5.5. Discussion 
Mucociliary clearance is a complex cleaning mechanism of the airways. Decisive 
parameters for mucociliary transport are ciliary beating, height of the periciliary layer 
(PCL) and viscoelastic properties of the mucus. Metachronal coordination of the beat 
pattern results in directional mucus transport only when transfer of kinetic energy 
from the cilia to the mucus layer is efficient. Thus, ciliary beat frequency (CBF) 
defines the maximum amount of kinetic energy to be transferred from the cilia to the 
upper mucus.  
As known from literature CBF is correlated to temperature. Clairy-Meinesz reported 
that human cilia are almost immotile at 5°C. From 9°C to 20°C CBF increased 
constantly and values approximately doubled as the temperature increased by 10°C. 
Between 20°C and 45°C CBF was found to be constant at around 8-11 Hz. At 50°C 
cilia rapidly became immotile and cooling did not restore ciliary motility (Clary-
Meinesz et al., 1992). Being aware of the CBF plateau between 20°C to 45°C and the 
comparability of human and chicken tissue at 33°C reported by Boek (Boek et al., 
1999a), all control experiments were realized at 33°C and 99% relative humidity. 
Rheological properties of the mucus are important parameters regarding coupling 
efficiency and correlation of mucus transport rates and rheological properties have 
already been reported (Shah and Donovan, 2007a). If the elastic and the viscous 
modulus are out of range, kinetic energy will be lost and the mucus will not be 
propelled at normal velocity. The experimental results in our study demonstrate 
efficient interaction of mucus and beating cilia. Mucus exhibited characteristic 
transparency and structure (streams, flakes) and entrapped particles were reproducibly 
and unidirectionally transported along the tracheal tissue. 
 
The results from the experiments at various temperatures clearly show a significant 
influence of temperature (P ≤ 0.001) on mucociliary transport (Figure 13). Reduced 
clearance rates can be explained by a combinatory effect of reduced or less 
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coordinated CBF and changes in mucus rheology (King, 1979, 1980; Rubin, 1988). 
Clearance velocity (2.39 ± 0.25) mm/min for the control experiments (33°C / 99%) 
were found to be comparable to data reported in literature. Tracheal mucociliary 
clearance rates reported for rats, guinea pigs and rabbits are (1.9 ± 0.7) mm/min,  
(2.7 ± 1.4) mm/min and (3.2 ± 1.1) mm/min, respectively (Felicetti et al., 1981). The 
only reported value for human mucus velocity in the main bronchi is about 
2.4 mm/min (Foster et al., 1980) which is in good accordance with our data. 
Decreasing relative humidity from 99% to 60% had no significant effect on transport 
rates and can be explained by a certain stability of MC function even under 
suboptimal environmental conditions. Thus, the duration of a single transport 
experiment (~10 min) might not be sufficient to change mucus properties, PCL height 
or CBF to a significant extent. Further reduction in relative humidity to 20% 
significantly influenced transport rates, suggesting that the model is sensitive for 
changes in humidity, moreover reflecting the in vivo situation where small changes 
should not affect MC dramatically. 
 
The choice of different active substances was made with respect to their impact on the 
mucociliary transport rate, respectively the CBF. All drugs tested had a significant 
influence on mucociliary clearance (Figure 14). Terbutalin and Propranolol are both 
influencing CBF via β-receptor related signaling pathways. Terbutalin, acting as a β-
adrenoceptor agonist, increases CBF by increasing intracellular levels of cyclic 
adenosine monophosphate (cAMP). On the contrary Propranolol, acting as β-blocker, 
reduces CBF via decrease of intracellular cAMP (Salathe, 2002). Mucociliary 
clearance for both drugs changes according to their respective pharmacological effect. 
For the experiments using Propranolol at various concentrations a concentration 
dependent effect could be determined, suggesting that the model exhibits sensitivity 
for drugs in a concentration dependent manner. The influence of N-Acetylcysteine 
(NAC) resulted in a significant reduction of mucociliary transport rates and can be 
explained by a significant change of mucus rheology. NAC is known to sever 
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disulfide bonds, thus diminishing crosslinking of the mucin network. In consequence, 
the viscosity as well as the elasticity of the mucus gel is reduced and the energy 
transfer from the cilia to the upper mucus layer is less efficient (Fuloria and Rubin, 
2000). 
 
Histochemical studies were performed to investigate functional development of 
ciliated cells, goblet cells, presence of surfactant proteins (SP-A), and possible 
differences compared to human tissue morphology. In the outcome, ECT morphology 
was found to be comparable to human tracheal tissue. Cilia length, cilia density and 
orientation of the basal bodies exhibit characteristic structure and orientation. 
Presence of goblet cells, mucus, and SP-A was successfully determined by Alcian 
blue staining and immuno-detection, respectively. Hence, all structures essentially 
required for mucociliary clearance and mucus particle interaction are present on the 
embryo chicken trachea. 
 
Several model systems based on frog palate, horse or bovine trachea are already 
available (King, 1998). Compared to those in vitro models the ECT model is favorable 
for several reasons:  1) Breeding eggs are commonly available in SPF (specific 
pathogen free) quality which reduces the costs and risks for biological contamination 
of the experimentalist and instruments to a minimum.  2) Eggs are easy to handle, do 
not need to be fed, and can be stored for up to 1 week prior to fully automated 
breeding.  3) As a result from 1) and 2) a high standardization for the ECT model is 
possible. This argument gains even more importance considering the fact that 
embryonic chicken trachea is an already validated model for investigating ciliary beat 
frequency (Boek et al., 1999a, b). 
These crucial aspects allow for generating a profound data basis. In experiments 
utilizing porcine or bovine tracheal tissue, such standardization may hardly be 
achieved as tissue from the local abattoir often undergoes critical but inevitable 
treatment e.g. cleaning with hot water steam, flames, and more. Transportation to the
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laboratory takes valuable time and experimental results may include artifacts. 
Moreover, housing conditions for the animals are not standardized, thus bacterial 
contamination or lung pneumonia can not be excluded. Raising animals for 
experimental use under best possible standardized conditions would be an option but 
suffers from increasing costs and the controversial discussion on ethical as well as 
regulatory aspects. 
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5.6. Conclusion 
The pulmonary route is considered as a promising target for drug and protein delivery. 
However, there are still open questions regarding long-term clearance of particles 
from the airways and mucus-particles interactions. Hitherto, ECT has been utilized 
and validated for CBF measurements under influence of various chemical substances. 
The aim of our study was to set up an in vitro model based on chicken trachea in order 
to investigate MC of particles under more complex constraints such as temperature, 
humidity and various drugs. Thus, MC in the experiments is a result of ciliary beating 
and effective energy transfer from cilia to the mucus. 
From our results we conclude that embryo chicken trachea can be employed to 
investigate the influence of cilio- and mucus-active drugs or particles on MC. The 
model shows a stability reflecting the in vivo situation where small changes are not 
supposed to impact dramatically on MC. Nevertheless, the ECT model is sensitive to 
changes in environmental conditions regarding temperature and humidity. 
Furthermore, the model allows for investigating the impact of drugs as could be 
shown for substances already known to influence clearance rates. As well this holds 
for the tissue response of the ciliotoxic substance Propranolol, which shows a 
concentration dependent decrease of MC as a result of the reduced ciliary function, as 
for Terbutalin and its clearance enhancing effect. Changes in mucus structure and the 
correlated rheological properties as achieved with N-Acetylcysteine can be monitored 
as well. 
 
Therefore, the ECT in vitro clearance model is a powerful tool to investigate 
particulate impact on the clearance functionality of the tracheal airway. Future 
experiments utilizing different sized and/or modified (nano) particles shall help 
to understand and identify decisive physico-chemical parameters for MC and to 
answer open questions on the particle long-term clearance phenomenon. 
  
 
 
6. Influence of Particle Size and Surface Properties on 
Mucociliary Particle Clearance 
 
 
 
 
 
 
Parts of this chapter will be submitted to the Journal of Controlled Release. 
 
Henning A., Schneider M., Nafee N., Rytting E., Kissel T., Grafahrend D., Klee D., 
Lehr C.-M. (2009): Influence of particle size and surface properties on mucociliary 
clearance from the airways. 
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6.1. Abstract 
Mucociliary clearance (MC), designed by evolution to eliminate inhaled and possibly 
noxious material from the airways, considerably limits the benefit of pulmonary drug 
delivery. Although the principal mechanism of MC seems to be understood, there are 
many open questions regarding physico-chemical factors determining the rate of 
mucociliary particle clearance. In this study a chicken trachea based in vitro model 
was used to investigate the effect of particle size and different particle surface 
properties on mucociliary particle clearance. The influence of particle size was 
investigated using polystyrene particles sized between 50 nm and 6000 nm. The effect 
of zeta-potential and mucoadhesive particle properties was tested using nanoparticles 
produced from different PLGA-copolymers, including chitosan-PLGA and PEG-
PLGA branched polyesters as therapeutic relevant materials. 
Experimental results showed no significant influence of polystyrene (PS) particle size 
on mucociliary transport rates (MTR): 50 nm, 100 nm, 1000 nm, and 6000 nm poly 
styrene particles were cleared at 3.2 ± 0.6 mm/min, 3.8 ± 0.8 mm/min, 3.8 ± 0.9 
mm/min, and 2.9 ± 0.6 mm/min, respectively. In contrast, particle clearance of 
different PLGA-co-polymeric nanoparticles exhibited significant differences: 
Chitosan-PLGA particles were transported by a factor of 4-5 slower than blank PLGA 
spheres: 0.7 ± 0.3 mm/min versus 3.2 ± 0.6 mm/min. High molecular weight 
PEG10kDa-PDLLA nanoparticles were transported at 2.8 ± 0.4 mm/min, whereas low 
molecular weight PEG5kDa-PLGA particles were transported significantly faster at  
5.9 ± 1.7 mm/min. 
 
Overall, particle size and zeta-potential seem to be relatively uncritical, whereas 
mucoadhesive interactions, determined by the particles’ chemical structure, can 
significantly impact on mucociliary particle clearance. Considering these findings 
in future drug formulation might help to control or even overcome mucociliary 
clearance and thereby optimize the benefit of inhalation therapy. 
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6.2. Introduction 
Mucosal barriers can be found at various sites of the human body, covering the 
gastrointestinal tract, female reproductive tract, intranasal epithelium, airways, and 
more. These mucosal barriers protect the human body from invading pathogens such 
as viruses, bacteria, and fungal spores. Pathogens as well as other insoluble particles 
normally adhere to the viscous mucus layer, where they are immobilized and will be 
eliminated by clearance mechanisms present at the specific site. 
Inside the respiratory system, inhaled material deposits in different lung regions 
depending on the aerodynamic particle diameter and the overall inhalation maneuver 
(Scheuch et al., 2007). Discrimination between the deposition sites is realized due to 
three different principle mechanisms: Brownian motion, sedimentation and impaction 
(Heyder, 1981). For particles sized smaller than 1 micron, Brownian motion will be 
the decisive mechanism for deposition, mainly in the alveolar regions of the lung. 
Particles sized 1–5 microns are suitable to enter and sediment within the 
tracheobronchial region, whereas particles larger than 5 microns will mainly be 
deposited in the oropharyngeal airways due to impaction (Oberdörster et al., 2005). 
Both the oropharyngeal and the tracheobronchial regions are part of the central lung 
and airways. Since there are different clearance mechanisms in the alveolar lung 
region, this must be considered if mucociliary particle clearance is the subject of 
investigation, as is here. 
Upon deposition in the airways, particles normally are trapped by the sticky mucus 
layer, lining the airway surface. Airway mucus is a gel composed of a 3-dimensional 
network of mucus glycoproteins (mucins). The mucin macromolecules consist of  
70 – 80% carbohydrate, 20% protein and 1 – 2% sulphate bound to oligosaccharide 
side chains (Fuloria and Rubin, 2000; Matsui et al., 1998). About 3% of the mucus 
layer consists of mucins, while 90–95% consists of water with electrolytes, serum 
proteins, immunoglobulins and lipids (Lethem, 1993; Verdugo, 1990). After 
entrapment by the mucus, particles are subsequently cleared from the deposition site
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 as the viscous mucus layer continuously moves proximally towards the upper end of 
the trachea. Unidirectional transport is realized due to controlled energy transfer from 
beating cilia to the upper mucus layer. Airway cilia (~200 cilia per cell) are hair like 
cell appendages (5-7 µm) beating in a metachronal coordinated wave pattern, thereby 
transferring kinetic energy to the upper mucus layer during the forward stroke (Sleigh 
et al., 1988). Finally, particles and mucus are swallowed and undergo further 
biochemical processing in the gastrointestinal tract. 
With respect to drug delivery, the lung’s unique barrier properties and large surface 
area (~140 m²) offer some promising advantages over other routes, e.g. oral drug 
delivery, which is often associated with poor drug permeability and the first-pass 
effect. Furthermore, there has been a sharp increase over the last 40 years in the global 
prevalence, morbidity, and mortality associated with asthma and COPD (Chronic 
Obstructive Pulmonary Disease), particularly in children. Approximately 300 million 
people worldwide currently have asthma, and its prevalence increases by 50% every 
decade. According to new estimates for 2030, COPD is predicted to become the third 
leading cause of death (WHO, 2008). As a consequence, more and more medical and 
also economical attention will be given to asthma and COPD therapy (Bousquet et al., 
2007). Therapeutic intervention for both diseases requires repeated daily drug 
application, depending on the actual status and severity of the disease. Here, 
mucociliary clearance (MC), originally designed to clear pathogens and other 
exogenous material from the airways, essentially limits the benefit of inhalation 
therapy: after the initial inhalation and deposition, drug particles are rapidly cleared 
and thus removed from the intended target site. 
Throughout the last decade, many different approaches have been realized in order to 
improve pulmonary drug delivery. Nevertheless, inhalation therapy still is problematic 
and related to many open questions on mucociliary particle clearance and mucus-
particle interaction. Former studies could show that MC removes all particles larger 
than 6 µm in diameter within 24 hours from the human airways, whereas for particles 
smaller than 6 µm a certain fraction was retained for more than 24 hours. 
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Interestingly, further reduction in particle size (<<6 µm) was correlated to an 
increasing fraction of long-term retained (> 24 h) particles (Möller et al., 2004; 
Scheuch and Stahlhofen, 1987; Stahlhofen et al., 1986; Stahlhofen et al., 1990). If this 
clearance phenomenon is correlated to particle size, the particle’s inherent physico-
chemical properties, or if other factors determine mucociliary particle clearance still 
has to be answered. 
Thus, the aim of our study was first to investigate the influence of particle size, and 
secondly to test the effects of different particle surface properties, determined by 
the chemical surface structure, on mucociliary particle clearance. Experiments were 
realized under standardized conditions using the previously established ECT in vitro 
model. The influence of particle size was investigated employing hydrophobic 
polystyrene (PS) model particles in a size range between 50 nm and 6000 nm. The 
effect of zeta-potential and particle surface properties was tested using various 
nanoparticles produced from different polymers (Table 1, Annex A.2), namely PLGA 
(I), chitosan-PLGA (II), PVA-g-PLGA (III), DEAPA-PVA-g-PLGA (IV), P(VS-VA)-
g-PLGA (V), PEG-PDLLA (VI), and PEG-PLGA (VII). 
 
Table 1: Polymers used for Particle Preparation and Abbreviations used in the Text. 
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PLGA (I) and chitosan-PLGA (II) were included to test the influence of a multi-
functional polymer which has been used for biomedical as well as drug delivery 
applications before (Agnihotri et al., 2004; Lehr, 2000; Rabea et al., 2003). Polymers 
III/IV/V (Rytting et al., 2008; Wang et al., 2008) were kindly provided by Prof. Dr. 
Thomas Kissel (Philipps Universität Marburg, Marburg, Germany). Polymers VI/VII 
(Grafahrend et al., 2008; Neuss et al., 2008) were kindly provided by Prof. Dr. Doris 
Klee (Chair of Textile Chemistry and Macromolecular Chemistry of RWTH Aachen, 
Aachen, Germany). 
 
Overall, identification of critical parameters for mucociliary particle clearance and 
mucus-particle interaction shall be employed to optimize the development of inhalable 
drug formulations. This in consequence may help to improve pulmonary drug delivery 
and to develop new therapeutic strategies for a continuously increasing number of 
patients suffering from asthma, COPD and other chronic respiratory diseases. 
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6.3. Materials and Methods 
6.3.1. Materials 
Inorganic salts (E. Merck, Darmstadt, Germany), fertilized chicken eggs (Lohmann 
Tierzucht GmbH, Cuxhaven, Germany), various sized (50nm/100nm/ 
1000nm/6000nm) polystyrene particles (Fluoresbrite®, Polysciences, Eppelheim, 
Germany), poly-D,L-lactide-co-glycolide (70:30) (Polysciences Europe GmbH, 
Eppelheim, Germany), polyvinyl alcohol; Mowiol® 4-88 (Kuraray Specialities 
Europe GmbH, Frankfurt, Germany), ultrapure Chitosan chloride: Protasan® UP 
CL113 with a molecular weight of <150 kDa (FMC BioPolymer AS, Oslo, Norway), 
ethyl acetate (Fluka Chemie GmbH, Buchs, Switzerland), poly(vinylalcohol)-graft-
poly(D,L-lactide-co-glycolide), diethyl-aminopropylamine-poly(vinylalcohol)-graft-
poly(D,L-lactide-co-glycolide), and poly- (vinylsulfonate-covinyl alcohol)-graft-
poly(D,L-lactide-co-glycolide), in the following termed polymers III/IV/V (Rytting et 
al., 2008; Wang et al., 2008); poly(ethyleneglycol)-block-poly(D,L-lactide) and 
poly(ethyleneglycol)-block-poly(D,L-lactide-co-glycolide), in the following termed 
polymers VI/VII (Grafahrend et al., 2008; Neuss et al., 2008). All chemicals used 
were of the highest available quality. 
 
6.3.2. Particles 
A) Polystyrene particles: 
 
Commercially available fluorescent polystyrene particles were used to investigate the 
influence of particle size and correlated factors on mucociliary particle clearance. 
Particles employed for experiments were sized 50nm, 100nm, 1000nm, and 6000nm, 
exhibiting all the same chemical polymer structure. 
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B) Polymeric nanoparticles produced from different polymers:  
 
In order to investigate the effects of zeta-potential, mucoadhesion, and chemical 
polymer structure on mucociliary particle clearance, various polymers, namely PLGA 
(I), chitosan-PLGA (II), PVA-g-PLGA (III), DEAPA-PVA-g-PLGA (IV), P(VS-VA)-
g-PLGA (V), PEG-PDLLA (VI), and PEG-PLGA (VII), were used to generate 
polymeric nanoparticles (Table 1). 
Particle preparation was according to established protocols using the solvent-
diffusion-evaporation (polymers I/II) or the solvent-displacement technique (polymers 
III-VII) (Ganachaud and Katz, 2005; Nafee et al., 2007; Ravi Kumar et al., 2004). To 
allow for fluorescence imaging of the particles, polymers were labeled by covalent 
binding of fluorescein amine or 7-MCCA (7-methoxy-coumarin-3-carbonylazide) 
following previously described protocols (Horisawa et al., 2002; Weiss et al., 2006). 
Size and zeta-potential of all particles were determined via Photon Correlation 
Spectroscopy and Laser-Doppler Anemometrie using a Zetasizer Nano ZS (Malvern 
Inst., Malvern, UK). Due to rapid sedimentation, 6000 nm polystyrene particles were 
not accessible for characterization using the Zetasizer Nano ZS. Here, particle size 
was determined using a MasterSizer 2000 (Malvern Inst., Malvern, UK), but these 
particles’ zeta potential could not be determined. 
 
6.3.3. Mucociliary Clearance Experiments 
Clearance experiments including trachea preparation and particle tracking were 
performed as described previously. Briefly, chicken eggs of SPF quality (specific 
pathogen free) were incubated in a breeding chamber (Hemel Breeding Instruments 
GmbH, Verl, Germany) at 37.8°C and 60% relative humidity. Embryonic chicken 
tracheas were harvested on day 19–20 and clearance experiments (20 min) were 
performed directly after dissection. Particle deposition on the trachea surface was 
realized using a Microsprayer™ (PennCentury Inc., Philadelphia, USA), originally
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developed for in vivo instillation experiments. Prior to particle deposition the tracheal 
tube was cut oblong resulting in two tracheal half-pipes. Particles were nebulized from 
aqueous suspension (50 µl) at constant mass concentrations (0.2 mg/ml) using a set-up 
previously established by Blank et al. (Blank et al., 2006). After particle deposition, 
the tracheal tissue was transferred to a temperature (33°C) and humidity (99%) 
controlled incubation chamber and subsequently placed under the microscope 
(AxioImager-M3, ZEISS, Germany). 
Mucociliary clearance of the particles was visualized via fluorescence microscopy 
(LD Plan-Neofluar 10x/0.30 20x/0.40, ZEISS, Germany) and recorded for 10–20 
seconds (AxioCam HSm, ZEISS, Germany) at various positions on the tracheal half-
pipes. Mucociliary transport rates (MTR) were calculated from 5-7 clearance 
experiments, considering 3-8 tracking videos and 3-8 particles tracked per video, 
respectively. All experimental results were examined for statistical differences (One 
Way-ANOVA, t-test) using routine statistical software (SigmaStat 3.0). 
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6.4. Results 
6.4.1. Influence of Particle Size 
Size of the polystyrene particles (PS) as measured by Photon Correlation 
Spectroscopy was in good agreement with diameters indicated by the manufacturer 
label. Zeta-potentials were found to be highly negative and comparable for all 
different sized polystyrene particles, as was expected due to the identical polymer 
composition. By stepwise increasing particle size from 50 nm to 6000 nm, the size 
correlated factors, such as particle surface and particle number, considerably 
decreased and hence varied between the polystyrene experiments. To consider this, 
relations of the particles diameter [d], surface [A], and number [N] were calculated 
from the results of polystyrene particle characterization (Table 2). 
 
Table 2: Results of Polystyrene (PS) Particle Characterization 
Size of the particles was in good agreement with diameters indicated by the manufacturer 
label. Particle diameter (d), polydispersity index (PDI), zeta-potential (Zeta), factors for 
particle diameter (fd), total surface (fA), and particle number (fN) in comparison to 6000 nm 
PS particles.  
 
Results for the polystyrene particle clearance are shown in Figure 19. An effect on 
mucociliary particle clearance was most presumable to occur for the 50 nm 
polystyrene particles since, comparing 6000 nm and 50 nm spheres, particle 
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diameter [d], surface [A], and number [N] differed by a factor of fd = 1.03 x 102, 
fA = 1.06 x 104, and fN = 1.09 x 106, respectively. Interestingly, the mucociliary 
transport rates (MTR) of differently sized polystyrene particles did not differ 
significantly (P < 0.05). MTR were found to be (3.2 ± 0.6) mm/min for 6000 nm 
particles, (3.8 ± 0.8) mm/min for 1000 nm particles, (3.8 ± 0.9) mm/min for 100 nm 
particles, and (2.9 ± 0.6) mm/min for 50 nm particles, suggesting that particle size 
does not appear to be a primary or critical factor for mucociliary particle clearance.  
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Figure 19: Clearance of Different-Sized Polystyrene (PS) Particles 
Results (mean ± SD) for polystyrene particle transport rates [mm/min] as determined from the 
clearance experiments. Numbers beside the bars designate the numbers of particles/tracheas 
investigated. Mucociliary transport rates (MTR) of different-sized polystyrene particles were 
not found to be significantly different (P < 0.05). 
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6.4.2. Influence of Particle Surface Properties 
Results from the clearance experiments of the polymeric nanoparticles are shown in 
Figure 20. Mucociliary transport rates (MTR) of the different polymeric particles were 
significantly different. Results of particle characterization were as expected according 
to the polymers chemical structure (Table 3). Particle size and zeta potential ranged 
between 90 nm to 400 nm, and -42 mV to +47 mV, respectively. 
 
 
 
 
 
 
 
 
Figure 20: Clearance of Different Polymeric Particles 
Results (mean ± SD) for particle transport rates [mm/min] as determined from the in vitro 
clearance experiments. Numbers beside the bars designate the numbers of particles 
investigated, e.g., “100/5” indicates 100 particles tracked on 5 tracheas. Transport rates of 
different polymeric particles show no significant difference (* P < 0.01; ** P < 0.001). 
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Table 3: Results of Polymeric Particle Characterization 
Results of particle characterization were as expected according to the polymers chemical 
structure. Particle diameter (d), polydispersity index (PDI), zeta-potential (Zeta), mucociliary 
transport rates (MTR).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Polymers I and II: 
MTR of equally sized PLGA (I) and chitosan-PLGA (II) particles were (3.2 ± 0.6) 
mm/min and (0.7 ± 0.3) mm/min, respectively. In comparison with blank PLGA (I) 
particles, this corresponds to a considerable reduction of chitosan-PLGA (II) particle 
clearance by a factor of 4-5. Clearance rates of PLGA (I) particles and similarly sized 
100 nm polystyrene particles (PS 0.1) were comparable: (3.2 ± 0.6) mm/min vs. (3.8 ± 
0.9) mm/min, which supports the outcome of the polystyrene particle experiments. 
Zeta-potential of the particles was according to the materials’ chemical structures  
(Table 3); a positive zeta-potential, induced by the primary amine-groups present 
within the chitosan polysaccharide structure, was determined for chitosan-PLGA (II) 
particles. Blank PLGA (I) nanospheres exhibited a negative zeta-potential due to the 
prevailing acidic structure of the polymer.  
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Polymers III-V: 
Clearance rates of PVA-g-PLGA (III), DEAPA-PVA-g-PLGA (IV), and P(VS-VA)-g-
PLGA (V) were (2.6 ± 0.5) mm/min, (1.6 ± 0.3) mm/min, and (1.6 ± 0.4) mm/min, 
respectively. Both DEAPA-PVA-g-PLGA (IV) and P(VS-VA)-g-PLGA (V) particles 
were transported significant slower than PVA-g-PLGA (III) particles, considered as 
the lead polymeric structure in this experimental polymer group (Table 1, Annex A.2). 
In parallel to chitosan-PLGA (II), the DEAPA-PVA-g-PLGA (IV) includes amine 
functions within the polymer structure, resulting in a positive zeta-potential of the 
DEAPA-PVA-g-PLGA (IV) particles. Comparing PVA-g-PLGA (III) and P(VS-VA)-
g-PLGA (V) particles, no amine groups were present in these polymers. Size and zeta-
potential for both PVA-g-PLGA (III) and P(VS-VA)-g-PLGA (V) particles was 
comparable and highly negative. Thus differences in particle MTR are presumably 
based on the polymers’ chemical structure. 
 
Polymers VI and VII: 
Surprisingly, clearance rates for PEG-PDLLA (VI) and PEG-PLGA (VII) particles 
were significantly different, although the particles’ zeta-potential values and polymer 
structures are comparable at first glance (Table 1, Annex A.2). The clearance rate of 
PEG-PDLLA (VI) particles was (2.8 ± 0.4) mm/min, whereas PEG-PLGA (VII) 
particles were transported at a rate of (5.9 ± 1.7) mm/min. Focusing more detailed on 
the polymers’ structure it became clear that the main difference was the molecular 
weight (MW) of the polyethylenglycol (PEG) used in the polymer synthesis: A high 
molecular weight PEG (10kDa) was employed for the PEG-PDLLA (VI) synthesis, 
whereas a low molecular weight PEG (5 kDa) was used for PEG-PLGA (VII). 
Therefore, it is suggested that mucociliary clearance for PEG-PDLLA (VI) and PEG-
PLGA (VII) particles mainly reflects influences based on the different PEG qualities. 
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6.5. Discussion 
It can be expected that molecular weight, chemical structure, charge, and the 
dimensional texture of a molecule have major influences on its interactions with and 
clearance from the human body. However, to what extent these factors may also affect 
mucociliary clearance had not been investigated previously. In view of the average 
tracheal clearance velocity, as determined by noninvasive radiological techniques in 
healthy non-smokers, mucociliary clearance varied between 4.0 and 6.0 mm/min 
(Hofmann and Asgharian, 2003). Based on these results, the International 
Commission on Radiological Protection (ICRP) and the National Council on 
Radiological Protection (NCRP) adopted an average tracheal clearance velocity of 
5.5 mm/min (ICRP, 1994; NCRP, 1997). Considering our results for particle 
clearance, the trachea-based in vitro model showed the fastest or “normal” 
mucociliary transport rates (~6.0 mm/min) with the PEG-PLGA (VII) particles. 
However, the transport rates of other polymeric nanoparticles varied significantly, as 
discussed below. 
 
6.5.1. Particle Size and Correlated Factors 
By today several studies were carried out to clarify the underlying mechanisms of 
long-term particle clearance (>24h) from the airways. As yet, particle size has been 
proposed to contribute to this clearance phenomenon (Scheuch and Stahlhofen, 1987; 
Stahlhofen et al., 1986; Stahlhofen et al., 1990). Though it could not be excluded that 
long-term clearance in these studies occurred due to particle deposition in the deep 
lung, where rapid particle clearance by the mucociliary elevator is not present. 
In our study, taking the clear advantage that alveolar deposition can be excluded in a 
trachea-based model per se, our first attempt was to investigate the influence of 
particle size, surface, and number on mucociliary particle clearance. According to 
theory a higher number of particles as well as a larger particle surface inevitably 
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results in a higher chance for mucus-particle interactions. Previously we assumed that, 
comparing 50 nm and 6000 nm particles and differences in particle size, total surface, 
and total number, the 50 nm particles have a much higher chance to influence 
mucociliary particle clearance and to interact with the mucin network. However, 
mucociliary transport rates for 50 nm up to 6000 nm sized polystyrene particles did 
not differ significantly even though particle size, surface and number varied 
tremendously by several orders of magnitude. Considering the overall results of 
mucociliary particle clearance, there was no conclusive correlation (R2) of clearance 
rates and particle size (d), surface (A), or volume (V): Rd2 = 0.1712, RA2 = 0.1061, 
RV2 = 0.0738. Hence, at this point it seems that particle properties other than size and 
correlated factors primarily affect airway particle clearance and long-term clearance, 
respectively. 
 
6.5.2. Particle Surface Properties 
The second objective was to investigate the effect of particle surface characteristics, 
determined by the materials’ chemical structure, on mucociliary particle clearance. 
Previously it was shown that polysaccharides and acrylic acids are capable to affect 
mucociliary clearance rates by changing the viscoelastic properties of the mucus 
(Shah and Donovan, 2007a, b). Here, we assumed that mucoadhesive properties and 
the zeta-potential of particles may also affect particle clearance velocity. 
 
Chitosan particles: 
Over the last two decades, chitosan has been used for various biomedical and drug 
delivery applications due to its biocompatibility, mucoadhesive properties and slight 
antimicrobial effects (Agnihotri et al., 2004; Lehr, 2000; Rabea et al., 2003). 
Mucoadhesive properties of chitosan particles are predominantly based on 
electrostatic attraction of primary amine groups present within the polysaccharide 
structure of chitosan (Sogias et al., 2008). In theory, strongly mucoadhesive particles 
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will be captured directly on top of the mucus layer, since penetration into the mucus 
layer is inhibited by particle adhesion to the outermost located mucins of the mucus 
layer. Interestingly, the chitosan-PLGA (II) particles were transported 4-5 times 
slower than the blank PLGA (I) nanospheres (Figure 20), although rapid 
immobilization on top of the mucus layer should result in spatially limited effects on 
mucociliary clearance. It is supposed that chitosan-PLGA (II) particles were either 
able to penetrate into the mucus layer, or the extent of mucus-particle interaction, even 
on top of the mucus layer, considerably changed the overall mucus transport 
properties. Here, fractional penetration of ~160 nm sized chitosan-PLGA (II) particles 
into the mucus layer seems to be reasonable, since rapid mucus penetration was also 
reported for considerably bigger (500 nm) particles (Lai et al., 2007).  
 
PEG-Particles: 
Mucociliary clearance rates for PEG-PDLLA (VI) and PEG-PLGA (VII) particles 
were significantly different although the zeta-potential values and polymer structures 
are comparable (Figure 20, Table 2). Focusing on the polymer structure, a clear 
difference is the PEG used in the polymer synthesis: A high molecular weight PEG 
(10 kDa) was used for PEG-PDLLA (VI) synthesis, whereas low molecular weight 
PEG (5 kDa) was used in the PEG-PLGA (VII). 
Previously it has been demonstrated that PEG molecular weight can significantly 
affect mucin-particle interaction by interpenetration of PEG-chains into the mucus 
network. Huang et al. (Huang et al., 2000) reported mucoadhesive PEG properties for 
high molecular weight PEG (> 10 kDa), whereas Lai et al. (Lai et al., 2007) could 
show strongly reduced mucoadhesive interaction for low molecular weight PEG (< 
2kDa) nanoparticles. Generally, PEG10kDa-PDLLA (VI) can be described as a di-block 
copolymer, whereas PEG5kDa-PLGA (VII) is a tri-block copolymer. From this 
structural aspect, the 10kDa PEG-block in the di-block copolymer per se is located at 
a higher ratio at the polymer-mucus interface, and thus has a higher probability to 
interact with the mucus network. On the other hand but due to the same structural 
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aspects, the 5kDa PEG-block within the PEG5kDa-PLGA (VII) tri-block has a lower 
potential to interact with the inner mucus structure. Therefore, differences between 
mucociliary particle clearance of PEG10kDa-PDLLA (VI) and PEG5kDa-PLGA (VII) 
particles presumably reflect the differences in mucus-particle interaction of the PEG 
polymers as is sketched in Figure 21. 
 
A) 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
Figure 21: Exemplary Scheme of PEG-Mucus Interaction 
The scheme shows the mucus layer and the incorporated mucin network A) prior, and B) after 
deposition of PEG-co-polymeric particles. A higher degree of PEG-chain interpenetration into 
the mucin network, as can be assumed for the 10kDa PEG-di-block particles, will influence 
the inner mucus structure and transport properties more significantly. 
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Looking at the clearance rates of PEG5kDa-PLGA (VII) versus blank PLGA (I) 
particles, this interpretation is even more corroborated since also the blank PLGA (I) 
particles exhibit a significantly reduced MTR in comparison to the PEG5kDa-PLGA 
(VII) particles. With respect to the potential influence of PDLLA vs. PLGA, a certain 
influence on particle transport might be assumed, but due to the results reported seems 
unlikely to be of significant importance here. 
 
Zeta-potential and chemical particle structure: 
In parallel to particle size, no reasonable correlation between zeta potential and 
mucociliary particle clearance could be observed (Figure 22). Overall correlation (R2) 
of zeta-potential and particle clearance was (R2 = 0.1762). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  22: 3D-Plot of Particle Size, Zeta-Potential, and Mucociliary Clearance 
For the different polymeric particles tested in this study, no reasonable correlation between 
particle size, zeta potential, and mucociliary particle clearance could be observed. 
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Though, looking at the chemical structure of the polymers (Table 2, Annex A.2), 
similar findings can be drawn as for the chitosan-PLGA (II) particles: In parallel to the 
mucoadhesive chitosan-PLGA (II), the DEAPA-PVA-g-PLGA (IV) also includes 
amine functions within the polymer structure. Consequently, the electrostatic interplay 
of mucus and DEAPA-PVA-g-PLGA (IV) particles is likely to be the reason for 
reduced particle clearance, too. Less efficient reduction of DEAPA-PVA-g-PLGA 
(IV) particle transport, as compared to chitosan-PLGA (II) particles, might occur due 
to sterical reasons: the DEAPA’s tertiary amine function may hinder the electrostatic 
interaction to a higher extent than primary amine groups present in chitosan.  
Comparing PVA-g-PLGA (III) and P(VS-VA)-g-PLGA (V) particles, no amine 
groups were present in these polymers. Size and the zeta potential values for both 
PVA-g-PLGA (III) and P(VS-VA)-g-PLGA (V) particles were comparable and highly 
negative. Thus, significant differences in particle clearance may be based on 
differences in the polymers’ chemical structures, i.e. the vinylsulfonate (VS) groups in 
the P(VS-VA)-g-PLGA particles. In general vinylsulfonate groups exhibit potent H-
bond acceptor qualities, which might be the source of interaction with the highly 
glycosylated mucins of the mucus layer and resulting differences in mucociliary 
clearance rates.  
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6.6. Conclusion 
Although there is a huge variety of application devices and drugs available, 
pneumology specialists agree on insufficient therapeutic standards regarding duration 
of drug effects and regional targeting within the respiratory system. In this context, 
mucociliary clearance acts as a major problem limiting the benefit of most inhalation 
therapies. Once the drug particles entered and deposited within the airways, 
mucociliary clearance immediately removes the particles from the intended target site. 
By today the most significant parameters for mucociliary particle clearance are not 
fully understood and still are under debate. Considering our results for in vitro 
mucociliary particle clearance and correlations with physico-chemical particle 
properties, several findings seem to be evident:  
 
1) Size and zeta-potential seem to be minor critical factors for mucociliary 
particle clearance, which could be shown for polystyrene as well as 
different polymeric nanoparticles covering a broad size and zeta-potential 
range.  
 
2) Interestingly, the chemical surface structure of the particles was found to 
be a most important factor for mucociliary particle clearance, offering 
possibilities to achieve faster or slower particle clearance. 
 
In the case of chitosan-PLGA and DEAPA-PVA-g-PLGA particles, the number and 
dimensional latitude of amine functions seem to affect particle clearance. These 
findings once more underline that chitosan and similar chemical modifications may be 
used if therapeutic interventions include beneficial effects due to adhesive interaction 
between the drug-carrier system and the mucosal barrier. For polyethylenglycol-
copolymers, mucociliary particle clearance seems to be effected by the PEG’s 
molecular weight: PEG10kDa-PDLLA particles showed reduced particle clearance, 
whereas PEG5kDa-PLGA particles were cleared at normal transport rates, compared to
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the ICRP’s standard value for average tracheal clearance rates. Although mucociliary 
clearance comprises a more complex situation than the systems studied by Huang et 
al. (Huang et al., 2000) or Lai et al. (Lai et al., 2007), the outcome of previous studies 
strongly support the experimental results presented here. At this point the demand for 
detailed investigations of mucus-particle and mucus-drug interactions to elucidate 
changes in the mucin network shall be clearly emphasized. With regard to the overall 
results from this study, a new and more concrete pulmonary drug delivery approach 
may be defined as:  
 
The ideal drug or drug loaded carrier system should be able to escape from 
mucociliary clearance if there are no or only minimal interactions with the mucus 
layer. Thereby the chance of rapid penetration into the periciliary layer, located 
underneath the mucus, is increased and interaction of the drug or carrier with the 
airway epithelium is more likely to occur.  
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7. Overall Conclusion and Outlook 
According to the World Health Organization (WHO) approximately 300 million 
people currently have asthma, and its prevalence increases by 50% every decade. 
Moreover, the WHO predicts Chronic Obstructive Pulmonary Disease (COPD) to 
become the 3rd leading cause of death by 2030 (WHO, 2008). Based on these facts it 
seems to be highly desirable to improve therapeutic options for inhalation therapy, 
currently strongly limited by the efficient lung clearance mechanisms. Moreover, 
designing pulmonary drug formulations, one should generally consider potential 
interactions with the mucus layer and mucociliary clearance as a key factor for 
therapeutic success of the delivery concept. 
 
In this context the ECT clearance model represents a valuable tool comprising 
scientific, economic, and ethical advantages to investigate mucociliary lung clearance 
and related topics. A most important result from the work presented is that the 
chemical surface structure of particles significantly influences mucociliary particle 
clearance, whereas particle size seems to act as a less critical factor. Here, in terms of 
risk assessment as well as basic research, further experiments employing a larger 
number of chemically defined particles may help to elucidate on critical chemical 
parameters for mucociliary particle clearance. Future experiments aiming to 
understand the fate of particles after interaction or penetration into the mucus network 
seem to be a major demand as it is not clear if the mucin network is a robust or highly 
delicate factor for functional mucus clearance. Further investigations on mucin-
particle interaction at the bulk- as well as microrheological level as well as 
microscopic studies are needed. 
 
With respect to the EU’s REACH initiative, the findings in this work underline the 
need for additional pulmonary risk assessment. Many inhalable micro- and nanosized 
materials were and still are employed in industrial manufacturing processes. These 
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materials often exhibit size-dependent physico-chemical properties and hence should 
be considered for more detailed investigation of airway particle clearance and 
toxicological effects. In this context employment of the ECT in vitro model can help 
to realize the ‘3R’ concept (Reduce, Refine, and Replace) in animal experiments, 
which was first stated in 1959 (Russel and Burch, 1959) and till today is strongly 
supported by the German ZEBET1 as well as international authorities like the 
ECVAM2.  
 
1 Zentralstelle zur Erfassung und Bewertung von Ersatz- und Ergänzungsmethoden zum Tierversuch (ZEBET) 
2 European Centre for the Validation of Alternative Methods (ECVAM) 
 
                                                                                                                                Annex 
 73
8. Annex 
A.1 Exemplary Image Sequence of Mucociliary Particle Clearance 
 
After deposition on the tracheal surface, carbon particles were only transported into 
proximal direction, i.e. towards the upper end of the trachea. As can be seen from the 
sequence, mucociliary clearance efficiently clears all carbon particles from the 
tracheal surface. The image sequence above shows 9 pictures, selected from a total of 
60 pictures, generated during a carbon particle clearance experiment. The course of 
time is represented from left to right as is also indicated by the relative time displayed 
in each image. Particle imaging was realized via transmission light microscopy (top-
view). Blurry regions in the middle of each picture result from depth of focus, a 
technical limitation given by the technical dimensions of each microscope objective. 
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A.2 Chemical Structure of Mono- and Polymers 
 
 
The table shows basic structures of all polymers employed in the particle clearance 
experiments. Chitosan and DEAPA structure includes primary and tertiary amine 
functions, respectively. Considering sterical aspects, the DEAPA’s tertiary amine 
function is shielded by ethyl groups which may be the reason for faster mucociliary 
clearance for DEAPA- as compared to chitosan-co-polymeric particles. 
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A.3 Experimental Set-up  
 
A) Microscope Set-up 
 
In order to realize mucociliary clearance experiments at different temperature and 
humidity levels, the upright microscope was fully integrated in a polycarbonate box, 
customized by LIS (Life Imaging Services, Reinach, CH). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
During the tracking experiments the microscope could be operated either manually or 
fully automated via the computer interface. Insulating properties of the overall Set-up 
were studied in order to ensure constant temperature and humidity levels during the 
particle clearance experiments. From these results (see 5.4.2. Validation of the 
Experimental Set-up) a general lead time could be defined to provide stable and 
defined experimental conditions. Illumination of particles was realized using either 
mercury vapor or LED technology (Colibri, ZEISS, Germany) as fluorescence light 
source, depending on imaging properties of the particles.  
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B) Incubation chamber 
 
The picture shows all individual parts of the incubation chamber, customized by LIS 
(Life Imaging Services, Reinach, CH). Subsequently, after the test particles were 
deposited on the tracheal surface, the chamber was closed via the magnetic seal. 
Different humidity levels in the closed chamber were realized by induction of a 
preconditioned airflow at the left side of the Teflon ring (a), placed between top (c) 
and base plate (b). During the validation experiments (5.4.2., page 34) the progression 
of temperature and relative humidity was measured directly in outlet airflow (right). 
To avoid fogging of the glass windows during the tracking experiments, the glass 
surface was modified using octadecyltrichlorosilane (OTS).  See also 5.3.3., page 29.  
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9. List of Abbreviations 
 
AT-I/II  Alveolar type I/II cells 
ATP   Adenosine triphosphate 
BCA   Bicinchoninic acid 
cAMP   Cyclic adenosine monophosphate 
CBF   Ciliary beat frequency 
CF   Cystic fibrosis 
COPD   Chronic obstructive pulmonary disease 
ECT   Embryonic chicken trachea 
ECVAM  European Centre for the Validation of Alternative Methods 
ICRP   International Commission on Radiological Protection 
MC   Mucociliary clearance 
MTR   Mucociliary transport rate 
MUCx   Mucin x encoding gene 
NAC   N-Acetylcysteine 
NCRP   National Council on Radiological Protection 
OTS   Octadecyltrichlorosilane 
PAGE   Polyacrylamide gel electrophoresis 
PCL   Periciliary layer 
PDD   Pulmonary drug delivery 
PDI   Polydispersity index 
PM   Particulate matter 
RPM   Rounds per minute 
SDS   Sodium dodecyl sulfate 
SEM   Scanning electron microscopy 
SP-A   Surfactant protein A 
SPF   Specific pathogen free 
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TEM   Transmission electron microscopy 
UFP   Ultra fine particles 
WHO   World Health Organization 
ZEBET  Zentralstelle zur Erfassung und Bewertung von Ersatz- und 
   Ergänzungsmethoden zum Tierversuch 
 
Polymer abbreviations see 6.2, page 52. 
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